Research Peptide Dosing & Reconstitution Reference (2026)

Research Peptide Dosing & Reconstitution Reference (2026)

Last updated: July 2026 · ThePeptide Research Team

Research-Use-Only Disclaimer. This article is a scientific reference summarizing the doses reported in published clinical trials and the arithmetic used to reconstitute lyophilized research compounds for laboratory measurement. It is not medical advice and does not tell any reader what to take. The compounds discussed are not approved by Health Canada or the U.S. FDA for the uses described here, are sold strictly for in-vitro and laboratory research only, and are not for human consumption. Nothing here should be interpreted as dosing guidance for a person. Always consult the primary peer-reviewed literature and qualified professionals.

Answer first: This guide summarizes the maintenance doses and titration schedules used in the published GLP-1 receptor agonist clinical trials (semaglutide, tirzepatide, retatrutide), lists the research dosing ranges most commonly cited for popular recovery and growth-hormone peptides (BPC-157, TB-500, CJC-1295, ipamorelin), and explains the universal arithmetic for reconstituting a lyophilized research peptide with bacteriostatic water and measuring a target mass on a U-100 syringe. It is intended purely as a laboratory reference. The trial figures are reported as historical scientific fact from the cited publications, and the commonly cited ranges are reference points drawn largely from preclinical and community protocols; none are recommendations.

Doses Used in the Published Clinical Trials

The table below reports the maintenance doses, escalation schemes, study duration, and mean weight change exactly as described in the cited peer-reviewed trials. These figures describe what was administered to enrolled human participants under clinical supervision in those studies. They are documented here for scientific reference only.

Compound Trial (citation) Studied maintenance dose(s) Escalation Duration Mean weight change
Semaglutide STEP 1 — Wilding JPH et al., N Engl J Med. 2021;384:989–1002 2.4 mg once weekly Escalated over 16 weeks: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg weekly at 4-week intervals 68 weeks −14.9%
Tirzepatide SURMOUNT-1 — Jastreboff AM et al., N Engl J Med. 2022;387:205–216 5, 10, 15 mg once weekly Initiated at 2.5 mg; escalated in 2.5 mg steps every 4 weeks 72 weeks −15.0% / −19.5% / −20.9% (vs −3.1% placebo)
Retatrutide Phase 2 — Jastreboff AM et al., N Engl J Med. 2023;389:514–526 Up to 12 mg once weekly Stepwise weekly titration to assigned target dose 48 weeks −24.2%
Retatrutide Phase 3 TRIUMPH-1 — Eli Lilly, 2026 12 mg once weekly Stepwise weekly titration 104 weeks −30.3%
Research-use reminder: these are historical trial figures reported for reference. They are not dosing instructions and do not authorize human use of any research compound.

Why Dose Escalation Was Used in the Trials

Every one of the trials above began at a low starting amount and stepped up gradually rather than beginning at the target maintenance dose. Within the trial design, the stated rationale for this titration was gastrointestinal tolerability: GLP-1 and dual/triple receptor agonists commonly produced dose-dependent nausea, vomiting, and diarrhea, and a slow ramp allowed those effects to attenuate before the next increase.

This is why, for example, the SURMOUNT-1 protocol initiated tirzepatide at 2.5 mg and raised it in 2.5 mg increments every four weeks, and why the STEP 1 semaglutide protocol spent 16 weeks reaching 2.4 mg. The four-week interval reflected the pharmacokinetics of these long-acting, once-weekly molecules reaching steady state. This section describes trial methodology only and is not a protocol for anyone to follow.

Commonly Cited Research Dosing Ranges by Compound

Researchers frequently ask what amounts are typically referenced for each peptide. The table below summarizes the ranges most commonly cited across the research literature and community research protocols. An important distinction applies: the GLP-1 metabolic peptides (semaglutide, tirzepatide, retatrutide) have been evaluated in large registered human clinical trials, so their figures are trial-established. The recovery and growth-hormone peptides (BPC-157, TB-500, CJC-1295, ipamorelin) have not been studied in large registered human efficacy trials — the ranges shown for them derive predominantly from preclinical (animal) studies and widely repeated research/community protocols, and should be read as reference points, not validated human doses.

Research-use reminder: every figure below is a commonly cited reference range for laboratory research context only. None of it is a dosing recommendation, and none of these compounds is approved by Health Canada or the FDA for human or veterinary use.
Compound Commonly cited research range Frequency as reported Evidence base
BPC-157 ~200–500 mcg per day (often cited near 250–500 mcg) Once daily, or split into two doses, in cited protocols Preclinical / community protocols
TB-500 (Thymosin Beta-4 fragment) ~2–5 mg per week Often split into 2 weekly doses; loading vs maintenance phases cited Preclinical / community protocols
BPC-157 + TB-500 blend Combined per-compound ranges above As per the individual compounds Preclinical / community protocols
CJC-1295 + Ipamorelin ~100 mcg of each per dose (the commonly cited "saturation dose"); some protocols cite 200–300 mcg/day total One to three times daily in cited protocols Mechanistic / community protocols
Semaglutide (GLP-1) Up to 2.4 mg once weekly (STEP 1 maintenance) Once weekly, after stepwise titration Registered human trial (NEJM 2021)
Tirzepatide (GIP/GLP-1) 5, 10, or 15 mg once weekly (SURMOUNT-1) Once weekly, after stepwise titration Registered human trial (NEJM 2022)
Retatrutide (triple agonist) Up to 12 mg once weekly (Phase 2 / TRIUMPH-1) Once weekly, after stepwise titration Registered human trial (NEJM 2023 / 2026)
The recovery and growth-hormone ranges are not established human therapeutic doses. They reflect what is most frequently reported in preclinical studies and research/community references, are provided strictly for research reference, and must not be interpreted as guidance to administer any substance to any organism.

How to Reconstitute a Lyophilized Peptide (Research Method)

Lyophilized (freeze-dried) research peptides arrive as a solid powder or cake and must be dissolved in a solvent before any laboratory measurement. The standard bench method is below. This describes handling of a research material in a lab, not preparation of anything for a person.

  1. Gather materials. The sealed peptide vial, bacteriostatic water as the reconstitution solvent, and a graduated U-100 insulin syringe. Wipe both vial stoppers with an alcohol swab.
  2. Decide your target concentration and calculate the solvent volume. Using the formula in the next section, choose how many millilitres of bacteriostatic water to add so that your desired measurement volumes fall on convenient syringe graduations.
  3. Draw the solvent. Pull the calculated volume of bacteriostatic water into the syringe.
  4. Add the solvent slowly down the vial wall. Inject the water so it runs gently down the inside glass wall onto the powder rather than blasting directly onto the cake.
  5. Swirl — do not shake. Gently swirl or roll the vial until the powder fully dissolves and the solution is clear. Shaking can shear and denature the peptide and creates foam.
  6. Label and store refrigerated. Note the concentration and date, then store the reconstituted vial refrigerated (2–8 °C).

Reconstitution Math & Concentration Chart

Reconstitution math is universal laboratory arithmetic. There are only two relationships to know.

Concentration (mg/mL) = peptide mass (mg) ÷ solvent volume (mL)
Volume to draw (units) = desired mass (mg) ÷ concentration (mg/mL) × 100

On a U-100 insulin syringe, the scale is marked in "units," where 100 units = 1 mL. So 0.1 mL is 10 units, 0.2 mL is 20 units, and so on. Multiplying the millilitre volume by 100 converts it to the units printed on the barrel, which is why the formula above ends in ×100.

The chart below works through common vial-and-solvent combinations. Choosing the solvent volume so your target lands on a round number of units makes measurement cleaner and reduces error.

Vial + solvent Resulting concentration Target mass Volume (mL) U-100 units
10 mg + 2 mL BAC water 5 mg/mL 0.5 mg 0.1 mL 10 units
10 mg + 2 mL BAC water 5 mg/mL 1 mg 0.2 mL 20 units
10 mg + 1 mL BAC water 10 mg/mL 1 mg 0.1 mL 10 units
5 mg + 2 mL BAC water 2.5 mg/mL 0.25 mg 0.1 mL 10 units
Research-use reminder: this arithmetic is for measuring a research material in the laboratory. It is not a directive to administer any amount to a human or animal.

Bacteriostatic Water vs Sterile Water

Bacteriostatic water is water containing 0.9% benzyl alcohol, an agent that inhibits bacterial growth and therefore allows a reconstituted vial to be accessed multiple times over an extended period. Sterile water contains no preservative and is intended for single use. For multi-use research handling of a reconstituted peptide, bacteriostatic water is the conventional solvent because its preservative extends usable bench life. ThePeptide stocks it in 10 mL and 3 mL formats.

Storage & Stability

Lyophilized (unreconstituted) vials are the most stable form. Kept sealed, cool, and away from light, freeze-dried peptide powder is typically stable long-term; many labs store powder frozen for extended periods.

Reconstituted vials are in solution and less stable. Once bacteriostatic water is added, store the vial refrigerated at 2–8 °C, protect it from light, and avoid repeated warming. The benzyl alcohol preservative supports a multi-week refrigerated bench window, but reconstituted material is generally best used within a few weeks. Avoid freeze-thaw cycling of reconstituted solution, as repeated cycles can degrade peptide integrity. Always inspect for cloudiness or particulates before use in any assay.

Frequently Asked Questions

How much bacteriostatic water do I add to a 10 mg peptide vial?

It depends on the concentration you want for measurement. Adding 2 mL to a 10 mg vial yields 5 mg/mL, so 0.5 mg falls on 10 units of a U-100 syringe. Adding 1 mL yields 10 mg/mL, so 1 mg falls on 10 units. Choose the volume that lands your targets on round units.

How many units is 1 mg on a U-100 syringe?

It depends on concentration. At 10 mg/mL, 1 mg equals 0.1 mL, which is 10 units. At 5 mg/mL, 1 mg equals 0.2 mL, which is 20 units. Use the formula: units = desired mass (mg) ÷ concentration (mg/mL) × 100. This is measurement arithmetic, not a dosing instruction.

What semaglutide dose was used in the STEP 1 trial?

In STEP 1 (Wilding et al., NEJM 2021), semaglutide was escalated over 16 weeks through 0.25, 0.5, 1.0, and 1.7 mg to a 2.4 mg once-weekly maintenance dose, with a mean weight change of −14.9% at 68 weeks. This is reported as a historical trial figure, not a recommendation.

What tirzepatide doses were studied in SURMOUNT-1?

SURMOUNT-1 (Jastreboff et al., NEJM 2022) studied 5, 10, and 15 mg once-weekly maintenance doses, initiated at 2.5 mg and escalated in 2.5 mg steps every 4 weeks. Mean weight changes at 72 weeks were −15.0%, −19.5%, and −20.9% versus −3.1% for placebo. Reported for reference only.

What retatrutide dose was studied?

The Phase 2 trial (Jastreboff et al., NEJM 2023) studied doses up to 12 mg once weekly, with roughly −24.2% mean weight reduction at 48 weeks. The Phase 3 TRIUMPH-1 program (Eli Lilly, 2026) reported 12 mg reaching −30.3% at 104 weeks. These are published trial figures, not usage guidance.

What strength of BPC-157 is commonly cited in research?

Across preclinical studies and research/community protocols, BPC-157 is most commonly referenced in the range of about 200–500 mcg per day, sometimes split into two doses. Unlike the GLP-1 compounds, BPC-157 has not been evaluated in large registered human efficacy trials, so this is a commonly cited reference range only — not an established or recommended human dose.

What are typical TB-500 and CJC-1295/ipamorelin research ranges?

TB-500 (a thymosin beta-4 fragment) is commonly cited around 2–5 mg per week, often split. CJC-1295 with ipamorelin is frequently referenced near 100 mcg of each per dose (the cited "saturation dose"), one to three times daily. These derive from preclinical and community protocols, not registered human trials, and are provided for research reference only.

Why did the trials escalate the dose gradually?

The published protocols used stepwise titration primarily for gastrointestinal tolerability. GLP-1 and multi-receptor agonists produced dose-dependent nausea and related effects, so a slow ramp at roughly four-week intervals let those effects settle and allowed the long-acting molecules to reach steady state before each increase.

How do I store reconstituted research peptides?

Store reconstituted vials refrigerated at 2–8 °C, protected from light, and avoid repeated warming or freeze-thaw cycling. The benzyl alcohol in bacteriostatic water supports a multi-week refrigerated window. Unreconstituted lyophilized powder is far more stable and can be kept frozen for long-term storage.

Bacteriostatic water vs sterile water — which is used?

Bacteriostatic water contains 0.9% benzyl alcohol, which inhibits bacterial growth and permits multiple accesses to a reconstituted vial over time. Sterile water has no preservative and is single-use. For multi-use laboratory handling, bacteriostatic water is the conventional reconstitution solvent.

Should I shake the vial to dissolve the powder faster?

No. Add the bacteriostatic water slowly down the inside wall of the vial and swirl gently until clear. Shaking can shear and denature the peptide and introduces foam. Gentle swirling fully dissolves lyophilized powder without compromising its integrity.

Related Research Resources

References

  1. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384:989–1002. DOI 10.1056/NEJMoa2032183. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
  2. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387:205–216. DOI 10.1056/NEJMoa2206038. PMID 35658024. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038 · https://pubmed.ncbi.nlm.nih.gov/35658024/
  3. Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389:514–526. DOI 10.1056/NEJMoa2301972. https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
  4. Additional indexed reference: https://pubmed.ncbi.nlm.nih.gov/33567185/
  5. TRIUMPH-1 Phase 3 program, Eli Lilly, 2026 (retatrutide 12 mg, −30.3% at 104 weeks).
Final Disclaimer. All content above is provided for laboratory and educational reference only. The trial doses cited describe what was administered in supervised clinical studies and are reported as scientific fact, not as guidance for any individual. The research compounds referenced are not approved by Health Canada or the FDA, are sold for in-vitro research use only, and are not for human or animal consumption. ThePeptide does not provide medical advice. Consult the primary peer-reviewed literature and qualified professionals before acting on any information here.
Back to blog